Guanfacine

Publication Details

Estimated reading time: 1 minute

CASRN: 29110-47-2

image 134996308 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

Because no information is available on the use of guanfacine during breastfeeding and its possible negative effects on lactation, other agents may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Published information on the effects of guanfacine on serum prolactin or on lactation in nursing mothers was not found as of the revision date. Guanfacine decreases basal serum prolactin in men and nonnursing women. Serum prolactin continues to decrease for at least 7 years during continuous use.[1] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

References

1.
Hauger-Klevene JH, Balossi EC, Scornavacchi JC. Effects of guanfacine on growth hormone, prolactin, renin, lipoproteins and glucose in essential hypertension. Am J Cardiol. 1986;57:27E–31E. [PubMed: 3513527] [CrossRef]

Substance Identification

Substance Name

Guanfacine

CAS Registry Number

29110-47-2

Drug Class

Breast Feeding

Lactation

Milk, Human

Antihypertensive Agents

Adrenergic alpha-2 Receptor Agonists

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.